Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 7/20 | 0.39 |
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823515 | 0.91 | KCNH2 (0.41) | ENPP2CNR1CNR2CXCR3KCNH2 | |
| SCHEMBL823449 | 0.89 | HRH3 (0.43) | CNR1CNR2CXCR3KCNH2HPGD | |
| SCHEMBL823442 | 0.88 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL823522 | 0.88 | ALDH1A1 (0.44) | CNR1CNR2CXCR3HPGD | |
| Hydrochloric Acid SCHEMBL826415 | 0.88 | HRH3 (0.42) | CNR1CNR2CXCR3KCNH2HPGD | |
| SCHEMBL823507 | 0.87 | CHRM3 (0.41) | CNR1CNR2CXCR3KCNH2HPGD | |
| SCHEMBL823478 | 0.86 | METTL3 (0.44) | ENPP2CNR1CNR2 | |
| SCHEMBL823460 | 0.85 | VEGFA (0.43) | ENPP2 | |
| SCHEMBL823453 | 0.83 | CHRM3 (0.43) | — | |
| SCHEMBL823461 | 0.83 | DRD2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| EP-2114903-B1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | ENPP2 2601/4885CNR1 1068/4885CNR2 1516/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | ENPP2 2601/4885CNR1 1068/4885CNR2 1516/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | ENPP2 2601/4885CNR1 1068/4885CNR2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.